HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Volition Beauty Grants Consumers A Role In Product Development

This article was originally published in The Rose Sheet

Executive Summary

Online beauty company invites new product ideas from consumers – as well as outside experts and even its own managers – and puts the best up for vote among its community members. Eight products have launched from Volition’s process to date, including four featured August 10 on QVC.

You may also be interested in...

Coty’s ‘Most Ambitious Fragrance Project To Date’; Head & Shoulders BARE; Cosmetic Launch News

Infiniment Coty Paris, launching globally in 2024, will “be to fragrance what [ultra-premium] Orveda is to skin care,” the company says. P&G touts Head & Shoulders BARE as the first anti-dandruff shampoo with only nine ingredients. More cosmetic launch news.

VC Funding For US Beauty Companies At Record High Already In 2018

Venture capitalists are racing to get a piece of emerging direct-to-consumer beauty and personal-care businesses, investing $812m in such companies in 2018 so far, according to data compiled by software-as-a-service firm Pitchbook.

Lauder Innovation Shift: Deemphasize Blockbusters, Let Winners Evolve

“The future of our innovation is changing,” according to leadership at Lauder, which is reducing innovation risk by cutting back on blockbuster launch investments. It’s a sensible strategic move at a time when consumers are avid about experimenting with and owning a rich variety of products, the firm suggests.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts